Skip to main content
SpringerLink
Log in

Cisplatin nephrotoxicity is not detected by urinary cell-cycle arrest biomarkers in lung cancer patients

  • Nephrology - Original Paper
  • Published:
International Urology and Nephrology Aims and scope Submit manuscript

Abstract

Purpose

Cisplatin is a chemotherapeutic agent with potential nephrotoxicity. Delayed increase in serum creatinine after cisplatin administration shows that serum creatinine may not be a sufficient marker for early detection of nephrotoxicity. Urinary insulin-like growth factor binding protein-7 (IGFBP7) and tissue inhibitor of metalloproteinases-2 (TIMP-2) which are cell-cycle arrest biomarkers have been proposed recently for early detection of acute kidney injury (AKI). Herein, we evaluated urinary TIMP-2/IGFBP7 levels before and after cisplatin administration to patients with lung cancer and their role was examined in the early diagnosis of AKI.

Methods

Patients with glomerular filtration rate above 60 mL/min who had cisplatin treatment were enrolled. Urinary TIMP-2/IGFBP7 and serum creatinine levels were measured before and at 24th hour after cisplatin administration. Serum creatinine level was also measured at 48th hour after treatment.

Results

Cisplatin-associated AKI was detected in 13 patients (28%) among the 45 patients enrolled. There was no difference between creatinine, IGFBP7 and (IGFBP7 × TIMP-2)/1000 levels before and after treatment; urinary TIMP-2 level at 24th hour was significantly higher than the level before the treatment (p = 0.02). (IGFBP7 × TIMP-2)/1000 values were not different between patients with or without AKI. The area under the curve of (IGFBP7 × TIMP-2)/1000 at 24th hour of the treatment was 0.46 (CI 0.26–0.67).

Conclusion

Although urinary IGFBP7 and TIMP-2 levels are used as biomarkers for early detection of AKI for patients in intensive care units and after surgery, they seem not to be useful for early detection of AKI due to cisplatin.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Lebwohl D, Canetta R (1998) Clinical development of platinum complexes in cancer therapy: an historical perspective and an update. Eur J Cancer 34(10):1522–1534

    Article  CAS  PubMed  Google Scholar 

  2. Cooley M, Davis LE, Stefano M, Abraham J (1994) Cisplatin: a clinical review. Part 1—current uses of cisplatin and administration guidelines. Cancer Nurs 17(3):173–184

    Article  CAS  PubMed  Google Scholar 

  3. Launay-Vacher V, Rey JB, Isnard-Bagnis C, Deray G, Daouphars M, European Society of Clinical Pharmacy Special Interest Group on Cancer Care (2008) Prevention of cisplatin nephrotoxicity: state of the art and recommendations from the European Society of Clinical Pharmacy Special Interest Group on Cancer Care. Cancer Chemother Pharmacol 61(6):903–909

    Article  CAS  PubMed  Google Scholar 

  4. Price PM, Safirstein RL, Megyesi J (2009) The cell cycle and acute kidney injury. Kidney Int 76(6):604–613

    Article  PubMed  PubMed Central  Google Scholar 

  5. Seo DW, Li H, Qu CK, Oh J, Kim YS, Diaz T, Wei B, Han JW, Stetler-Stevenson WG (2006) Shp-1 mediates the antiproliferative activity of tissue inhibitor of metalloproteinase-2 in human microvascular endothelial cells. J Biol Chem 281(6):3711–3721

    Article  CAS  PubMed  Google Scholar 

  6. Cornelison TL, Reed E (1993) Nephrotoxicity and hydration management for cisplatin, carboplatin and ormaplatin. Gynecol Oncol 50(2):147–158

    Article  CAS  PubMed  Google Scholar 

  7. Yao X, Panichpisal K, Kurtzman N, Nugent K (2007) Cisplatin nephrotoxicity: a review. Am J Med Sci 334(2):115–124

    Article  PubMed  Google Scholar 

  8. Gaspari F, Cravedi P, Mandalà M, Perico N, de Leon FR, Stucchi N, Ferrari S, Labianca R, Remuzzi G, Ruggenenti P (2010) Predicting cisplatin-induced acute kidneyinjury by urinary neutrophil gelatinase-associated lipocalin excretion: a pilot prospective case–control study. Nephron Clin Pract 115(2):c154–c160

    Article  CAS  PubMed  Google Scholar 

  9. Lin HY, Lee SC, Lin SF, Hsiao HH, Liu YC, Yang WC, Hwang DY, Hung CC, Chen HC, Guh JY (2013) Urinary neutrophil gelatinase-associated lipocalin levels predict cisplatin-induced acute kidney injury better than albuminuria or urinary cystatin C levels. Kaohsiung J Med Sci 29(6):304–311

    Article  CAS  PubMed  Google Scholar 

  10. Shinke H, Masuda S, Togashi Y, Ikemi Y, Ozawa A, Sato T, Kim YH, Mishima M, Ichimura T, Bonventre JV, Matsubara K (2015) Urinary kidney injury molecule-1 and monocyte chemotactic protein-1 are noninvasive biomarkers of cisplatin-induced nephrotoxicity in lung cancer patients. Cancer Chemother Pharmacol 76(5):989–996

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Faubel S, Lewis EC, Reznikov L, Ljubanovic D, Hoke TS, Somerset H, Oh DJ, Lu L, Klein CL, Dinarello CA, Edelstein CL (2007) Cisplatin-induced acute renal failure is associated with an increase in the cytokines interleukin (IL)-1beta, IL-18, IL-6, and neutrophil infiltration in the kidney. J Pharmacol Exp Ther 322(1):8–15

    Article  CAS  PubMed  Google Scholar 

  12. Rodier F, Campisi J, Bhaumik D (2007) Two faces of p53: aging and tumor suppression. Nucleic Acids Res 35:7475–7484

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Kashani K, Al-Khafaji A, Ardiles T et al (2013) Discovery and validation of cell cycle arrest biomarkers in human acute kidney injury. Crit Care 17(1):R25

    Article  PubMed  PubMed Central  Google Scholar 

  14. Koyner JL, Shaw AD, Chawla LS, Hoste EA, Bihorac A, Kashani K, Haase M, Shi J, Kellum JA (2015) Sapphire Investigators: tissue Inhibitor Metalloproteinase-2(TIMP-2)·IGF-Binding Protein-7 (IGFBP7) Levels Are Associated with Adverse Long-Term Outcomes in Patients with AKI. J Am Soc Nephrol 26(7):1747–1754

    Article  CAS  PubMed  Google Scholar 

  15. Bihorac A, Chawla LS, Shaw AD et al (2014) Validation of cell-cycle arrest biomarkers for acute kidney injury using clinical adjudication. Am J Respir Crit Care Med 189(8):932–939

    Article  CAS  PubMed  Google Scholar 

  16. Hoste EA, McCullough PA, Kashani K et al (2014) Sapphire Investigators: derivation and validation of cutoffs for clinical use of cell cycle arrest biomarkers. Nephrol Dial Transpl 29(11):2054–2061

    Article  CAS  Google Scholar 

  17. Meersch M, Schmidt C, Van Aken H, Martens S, Rossaint J, Singbartl K, Görlich D, Kellum JA, Zarbock A (2014) Urinary TIMP-2 and IGFBP7 as early biomarkers of acute kidney injury and renal recovery following cardiac surgery. PLoS ONE 9(3):e93460

    Article  PubMed  PubMed Central  Google Scholar 

  18. Gocze I, Koch M, Renner P, Zeman F, Graf BM, Dahlke MH, Nerlich M, Schlitt HJ, Kellum JA, Bein T (2015) Urinary biomarkers TIMP-2 and IGFBP7 early predict acute kidney injury after major surgery. PLoS ONE 10(3):e0120863

    Article  PubMed  PubMed Central  Google Scholar 

  19. Kimmel M, Shi J, Latus J, Wasser C, Kitterer D, Braun N, Alscher MD (2016) Association of renal stress/damage and filtration biomarkers with subsequent AKI during hospitalization among patients presenting to the emergency department. Clin J Am Soc Nephrol 11(6):938–946

    Article  PubMed  Google Scholar 

  20. Bell M, Larsson A, Venge P, Bellomo R, Mårtensson J (2015) Assessment of cell-cycle arrest biomarkers to predict early and delayed acute kidney injury. Dis Mark 2015:158658

    Google Scholar 

  21. Prof. Dr. İrfan Şencan, Prof. Dr. Gülsün Nurhan İnce (2016) Türkiye Kanser İstatistikleri. http://kanser.gov.tr/Dosya/ca_istatistik/ANA_rapor_2013v01_2.pdf

Download references

Acknowledgements

The research received no specific grant from any funding agency.

Author information

Authors and Affiliations

  1. Department of Internal Medicine, Okmeydani Training and Research Hospital, Istanbul, Turkey

    Zeki Toprak, Serife Aysen Helvaci, Ilkim Deniz Toprak, Yasin Kutlu & Tufan Tukek

  2. Department of Nephrology, Okmeydani Training and Research Hospital, Istanbul, Turkey

    Egemen Cebeci

  3. Department of Medical Oncology, Okmeydani Training and Research Hospital, Istanbul, Turkey

    Abdullah Sakin

Authors
  1. Zeki Toprak
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Egemen Cebeci
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Serife Aysen Helvaci
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ilkim Deniz Toprak
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Yasin Kutlu
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Abdullah Sakin
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Tufan Tukek
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Zeki Toprak.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

This study was approved by the research ethics board of Okmeydani Training and Research Hospital. All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.

Informed consent

Informed consent was obtained from all individual participants included in the study.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Toprak, Z., Cebeci, E., Helvaci, S.A. et al. Cisplatin nephrotoxicity is not detected by urinary cell-cycle arrest biomarkers in lung cancer patients. Int Urol Nephrol 49, 1041–1047 (2017). https://doi.org/10.1007/s11255-017-1556-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11255-017-1556-4

Keywords

Search

Navigation